We are all about Compressing Development Timelines. We utilize refined partner-driven models, take advantage of complex and highly developed network of suppliers, service firms, academic centers, development and manufacturing centers which drive Phase I entry of new therapeutics We have refined novel ways to trim development activities to the essential regulatory core and tightly focus efforts on cost effective aspects designed to increase product value, in months rather than years We reduce technology, regulatory risks, take advantage of global arbitrage at an earlier stage of development and acquire critical technology which may provide greater value Take advantage of an environment which allows venture firms to finance projects rather than companies